Evaluation of bleeding adverse events associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system .

CONCLUSION: Reports on bleeding differed among P2Y12 inhibitors with respect to type and outcome. Although FAERS is subject to significant limitations, our results show that the safety profiles of P2Y12 inhibitors in the spontaneous reporting system did not differ from the results of premarketing studies. . PMID: 30738497 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30738497?dopt=Abstract

Source: International Journal of Clinical Pharmacology and Therapeutics - February 12, 2019 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research

Evaluation of bleeding adverse events associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system .

Evaluation of bleeding adverse events associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system .